Rosalind Advisors, Inc.
Reported holdings as of Q2 2026, from 11 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| DELCATH SYS INC | DCTH | $41.6M | 3,300,389 | +3.13pp | 11q | HELD | |
| FENNEC PHARMACEUTICALS INC | FENC | $34.3M | 3,188,001 | +5.54pp | 7q | +9.6%+$3.0M | |
| XERIS BIOPHARMA HOLDINGS INC | XERS | $23.0M | 2,908,981 | +1.03pp | 11q | -10.0%-$2.6M | |
| SAVARA INC | SVRA | $19.6M | 3,178,121 | +0.24pp | 7q | -0.8%-$157.7K | |
| VERASTEM INC | VSTM | $15.2M | 3,986,509 | +1.10pp | 7q | +86.4%+$7.1M | |
| X4 PHARMACEUTICALS INC | XFOR | $15.0M | 3,214,766 | +0.24pp | 4q | HELD | |
| EYEPOINT INC | EYPT | $14.1M | 988,230 | -0.12pp | 4q | -4.7%-$693.7K | |
| CYBIN INC | HELP | $12.9M | 1,956,814 | +1.85pp | 7q | +27.7%+$2.8M | |
| VOR BIOPHARMA INC | VOR | $11.9M | 648,600 | -0.58pp | 2q | -7.3%-$946.3K | |
| VAXCYTE INC | PCVX | $11.6M | 200,000 | -2.45pp | 2q | -31.0%-$5.2M | |
| MEDIWOUND LTD | MDWD | $11.0M | 749,054 | -0.76pp | 11q | HELD | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $7.4M | 200,000 | -1.44pp | 2q | -39.4%-$4.8M | |
| BIOCRYST PHARMACEUTICALS INC | BCRX | $7.2M | 721,504 | -0.85pp | 2q | -21.8%-$2.0M | |
| PROFOUND MED CORP | PROF | $5.5M | 828,118 | -0.11pp | 11q | HELD | |
| TALPHERA INC | TLPH | $5.3M | 5,169,501 | +0.97pp | 11q | +54.1%+$1.9M | |
| ATEA PHARMACEUTICALS INC | AVIR | $5.0M | 1,070,550 | -0.68pp | 2q | -8.6%-$471.1K | |
| MYOMO INC | MYO | $3.8M | 3,637,886 | +0.36pp | 11q | -5.4%-$217.8K | |
| OVID THERAPEUTICS INC | OVID | $3.0M | 1,107,994 | +0.12pp | 2q | HELD | |
| NEURAXIS INC | NRXS | $3.0M | 508,055 | +0.42pp | 3q | +77.6%+$1.3M | |
| ABIVAX SA | ABVX | $2.8M | 20,869 | - | new | NEW | |
| INSPIREMD INC | NSPR | $2.7M | 3,905,743 | -1.54pp | 11q | HELD | |
| REGENTIS BIOMATERIALS LTD | RGNT | $2.5M | 701,685 | +0.61pp | 3q | +179.0%+$1.6M | |
| SELLAS LIFE SCIENCES GROUP I OPT | SLS | $2.3M | options only | - | new | OPTIONS | |
| POLYPID LTD | PYPD | $2.0M | 389,455 | -0.32pp | 10q | -34.9%-$1.1M | |
| BIOFRONTERA INC | BFRI | $1.2M | 1,275,609 | +0.07pp | 10q | +9.6%+$105.6K | |
| KURA ONCOLOGY INC | KURA | $1.1M | 100,000 | +0.08pp | 6q | HELD | |
| SPRUCE BIOSCIENCES INC | SPRB | $1.1M | 20,000 | - | new | NEW | |
| AQUESTIVE THERAPEUTICS INC | AQST | $1.0M | 250,000 | -0.03pp | 2q | HELD | |
| ONKURE THERAPEUTICS INC | OKUR | $684.0K | 150,000 | -0.48pp | 3q | -66.2%-$1.3M | |
| PEPGEN INC | PEPG | $630.0K | 350,000 | - | new | NEW | |
| CG ONCOLOGY INC OPT | CGON | $375.1K | options only | - | new | OPTIONS | |
| EYEPOINT INC OPT | EYPT | $130.8K | options only | - | new | OPTIONS | |
| ISHARES TR OPT | IWM | $110.0K | options only | - | new | OPTIONS | |
| SPDR SERIES TRUST OPT | XBI | $35.1K | options only | - | new | OPTIONS | |
| 88032L955 OPT | $13.9K | options only | - | new | OPTIONS |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $208.0M | 77.3% |
| Medical Devices | $61.0M | 22.7% |
| Not classified | $159.1K | 0.1% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $269.2M | 35 | 9 | 7 | 11 | 10 | 74.0% | 45 |
| Q1 2026 | $248.9M | 36 | 12 | 6 | 8 | 15 | 65.9% | 44 |
| Q4 2025 | $284.5M | 39 | 9 | 7 | 7 | 9 | 60.7% | 43 |
| Q3 2025 | $292.6M | 39 | 11 | 11 | 7 | 9 | 60.1% | 44 |
| Q2 2025 | $210.9M | 37 | 12 | 7 | 9 | 9 | 62.3% | 45 |
| Q1 2025 | $205.6M | 34 | 7 | 8 | 9 | 13 | 63.4% | 44 |
| Q4 2024 | $195.6M | 40 | 22 | 5 | 7 | 15 | 65.8% | 45 |
| Q3 2024 | $156.2M | 33 | 5 | 9 | 9 | 11 | 70.4% | 30 |
| Q2 2024 | $130.0M | 39 | 8 | 12 | 5 | 2 | 59.8% | 12 |
| Q1 2024 | $107.0M | 33 | 11 | 2 | 11 | 8 | 58.3% | 25 |
| Q4 2023 | $121.4M | 30 | 0 | 0 | 0 | 0 | 61.9% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.